Overview

PhIb Study Evaluating Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC

Status:
Recruiting
Trial end date:
2024-12-15
Target enrollment:
Participant gender:
Summary
This is a prospective, open label, interventional trial beginning with a phase 1b safety run-in followed by an expansion cohort.
Phase:
Phase 1
Details
Lead Sponsor:
University of Utah
Treatments:
Ipilimumab
Osimertinib